Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: R-Pharm
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for OKZ-64](https://pryzm-maps.s3.us-west-2.amazonaws.com/508current_maps.png)
Countries in Clinic: Russia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Lung Diseases, Interstitial
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CL04041109 | P3 |
Recruiting |
Lung Diseases, Interstitial |
2026-06-20 |